News

  • 21 November 2017

    Galapagos reports Phase II data of cystic fibrosis drug

    Belgium-based biotechnology firm Galapagos has reported positive topline data from the Phase II ALBATROSS clinical trial of GLPG2222 in patients with heterozygous class III/F508del cystic fibrosis transmembrane conductance regulator (CFTR).

  • 20 November 2017

    Celldex starts Phase II trial for head and neck cancer

    Celldex Therapeutics has started patient enrolment in a Phase II clinical trial of CDX-3379 to be evaluated in combination with cetuximab (Erbitux) for the treatment of refractory, advanced head and...

  • 17 November 2017

    Rafael Pharma launches Phase I pancreatic cancer trial

    US-based Rafael Pharmaceuticals has launched a Phase I clinical trial of its drug candidate CPI-613 to be assessed in combination with chemotherapeutics, gemcitabine, and nab-paclitaxel to treat patients with pancreatic...